Internal Medicine Alert
RSSArticles
-
Long-term Weight Loss Rivals Medications and Ablation for AF Rhythm Control
The authors conclude long-term sustained weight loss was possible and was associated with a significant reduction in atrial fibrillation burden.
-
Provocative Cardiovascular Testing for Everyone with Chest Pain?
ABSTRACT & COMMENTARY: Pain or not, it's hard to take money out of the medical equation.
-
Clinical Brief
Briefs -
Dulaglutide Injection (Trulicity™)
The FDA has approved a third long-acting, once-weekly, glucagon-like peptide (GLP-1) receptor agonist for the treatment of type 2 diabetes mellitus, joining exenetide ER and albiglutide. Dulaglutide is made up of two identical human-based GLP-1 analogs linked to a modified human IgG4 Fc fragment. This makes the molecule resistant to degradation by DPP-4, slows absorption, reduces renal clearance, and extends the elimination half-life to approximately 5 days. Dulaglutide is marketed by Eli Lilly as Trulicity.
-
Angiotensin Receptor Blockers for Hypertension
Angiotensin receptor blockers (ARBs) are often used as first-line therapy for the treatment of systemic hypertension because of their perceived efficacy and relatively low incidence of adverse effects.
-
Colchicine for Recurrent Pericarditis
Although colchicine has been shown to be effective for the treatment of acute pericarditis and first recurrences, little information exists about its use in patients with multiple recurrences.
-
Clinical Briefs
Distinguishing the major differences within the class of beta-blockers; delay in the diagnosis of hepatocellular carcinoma; and a closer look at an under-recognized form of orthostatic hypotension.
-
Isavuconazonium Sulfate Capsules and Injection (Cresemba ®)
Isavuconazole provides an alternative for the treatment of invasive aspergillosis and mucormycosis.
-
Can Dietary Intervention Delay the Onset of Alzheimer’s Disease?
Targeted nutritional interventions are an evidence-based and safe means of reducing the risk of Alzheimer's disease and cognitive decline.
-
Lowering LDL with Ezetimibe
The combination of simvastatin and ezetimibe resulted in significantly lower LDL levels and a lower risk of cardiovascular events than occurred in patients who are treated with statin monotherapy.